Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Rate01:11

Hazard Rate

458
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
458
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

1.1K
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
1.1K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

648
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
648
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

449
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
449
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

637
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
637
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

866
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
866

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.

Blood advances·2026
Same author

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

American journal of hematology·2026
Same author

MELODY: Mediation Analysis in Logistic Regression for High-Dimensional Mediators and a Binary Outcome.

Genetic epidemiology·2026
Same author

MELODY: Mediation Analysis in Logistic Regression for High-Dimensional Mediators and a Binary Outcome.

bioRxiv : the preprint server for biology·2025
Same author

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia.

Blood advances·2025
Same author

A Biomarker Signature-Guided Clinical Trial Design for Precision Medicine.

Statistics in medicine·2025
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 21, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K

Semiparametric accelerated failure time cure rate mixture models with competing risks.

Sangbum Choi1, Liang Zhu2, Xuelin Huang3

  • 1Department of Statistics, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, South Korea.

Statistics in Medicine
|October 7, 2017
PubMed
Summary
This summary is machine-generated.

This study introduces a novel cure-mixture model for analyzing survival data with competing risks and a cured fraction. The method offers insights into treatment effects on both cured and uncured patient groups.

Keywords:
competing riskscure fractionkernel smoothingmixture modelnonparametric likelihoodsubdistribution

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

944

Related Experiment Videos

Last Updated: Feb 21, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

944

Area of Science:

  • Biostatistics
  • Survival Analysis
  • Medical Statistics

Background:

  • Chronic disease treatments improve survival, necessitating models for non-ignorable cured proportions.
  • Competing risks with multiple endpoints complicate survival data analysis.
  • Existing proportional hazards models for competing risks have limitations.

Purpose of the Study:

  • To propose an alternative regression approach for survival data with competing risks and a cure fraction.
  • To develop a cure-mixture modeling framework using semiparametric accelerated failure time models.
  • To provide a method for assessing overall treatment effects and their impact on mixture components.

Main Methods:

  • Utilized semiparametric accelerated failure time models for cause-conditional survival functions.
  • Integrated models via a multinomial logistic model within a cure-mixture framework.
  • Employed nonparametric kernel-based maximum likelihood estimation and resampling for parameter and variance estimation.

Main Results:

  • The proposed cure-mixture approach effectively analyzes competing risks with a cure fraction.
  • The method allows for the determination of overall treatment effects.
  • Demonstrated utility through simulation studies and application to sarcoma data.

Conclusions:

  • The cure-mixture model offers a flexible and insightful approach to complex survival data.
  • This method enhances understanding of treatment efficacy in the presence of cure fractions and competing risks.
  • The approach is validated for practical application in medical research.